Skip to Content

Incivek Approval History

Incivek (telaprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of chronic hepatitis C (CHC).

Development History and FDA Approval Process for Incivek

May 23, 2011Approval FDA Approves Incivek (telaprevir) for People with Hepatitis C
Apr 29, 2011FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C
Jan 20, 2011U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C
Nov 23, 2010Vertex Completes New Drug Application for Telaprevir for Hepatitis C

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.